XBiotech(XBIT)
$1.95-0.02 (-1.02%)
XBIT
XBiotech financials statements
$1.95
At close:-0.02 (-1.02%)
XBiotech (XBIT) Ratios
345 Followers
XBiotech Ratios
XBIT's free cash flow for Q2 2026 was $-4.51M. For the 2026 fiscal year, XBIT's free cash flow was increased by $3.00K and operating cash flow was $-4.51M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 16.01 | 11.56 | 33.07 | 54.07 | 71.49 |
| Quick Ratio | 16.01 | 11.56 | 33.07 | 54.07 | 71.49 |
| Cash Ratio | 15.83 | 11.43 | 32.79 | 38.69 | 68.63 |
| Solvency Ratio | -4.51 | -2.19 | -2.94 | -5.31 | -2.55 |
| Operating Cash Flow Ratio | -5.03 | -2.05 | -3.07 | -3.65 | 20.11 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -3.02 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 117.22M | $ 157.74M | $ 193.95M | $ 214.14M | $ 241.08M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.09 | 1.04 | 1.02 | 1.02 |
| Debt Service Coverage Ratio | -497.34 | -3.25 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -632.78 | -52.63 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.36 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 2.88 | 4.51 | 8.86 | 4.93 | 10.56 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 83.77% | 68.36% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -860.10% | -136.36% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -794.91% | -121.96% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -860.10% | -136.36% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -837.61% | -138.40% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -820.45% | -94.67% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -820.45% | -94.67% |
| Net Income Per EBT | 100.52% | 99.92% | 101.00% | 97.95% | 68.40% |
| EBT Per EBIT | 81.36% | 90.80% | 64.82% | 97.38% | 101.50% |
| Return on Assets (ROA) | -30.34% | -19.35% | -10.84% | -13.37% | -6.33% |
| Return on Equity (ROE) | -32.45% | -21.14% | -11.22% | -13.69% | -6.46% |
| Return on Capital Employed (ROCE) | -39.17% | -23.08% | -17.01% | -14.25% | -9.23% |
| Return on Invested Capital (ROIC) | -39.17% | -21.85% | -17.01% | -13.96% | -6.31% |
| Return on Tangible Assets | -30.34% | -19.35% | -10.84% | -13.37% | -6.33% |
| Earnings Yield | -62.50% | -32.02% | -20.25% | -30.79% | -5.21% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 2.27 | 2.05 |
| Payables Turnover | 1.10 | 0.00 | 0.00 | 0.27 | 2.81 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.15 | 0.65 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 |
| Cash Conversion Cycle | -332.31 | 0.00 | 0.00 | -1189.54 | 47.90 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 160.56 | 177.66 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 332.31 | 0.00 | 0.00 | 1350.11 | 129.76 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 160.56 | 177.66 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.31 | -1.02 | -0.62 | -0.49 | 2.31 |
| Free Cash Flow Per Share | -1.32 | -1.06 | -0.63 | -0.51 | 2.19 |
| Dividend Paid and CapEx Coverage Ratio | -138.13 | -23.74 | -51.73 | -25.34 | 0.88 |
| Capital Expenditure Coverage Ratio | -138.13 | -23.74 | -51.73 | -25.34 | 19.70 |
| Operating Cash Flow Coverage Ratio | 0.00 | -3.02 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -3.70 | 3.78 |
| Free Cash Flow Yield | -55.18% | -26.82% | -15.74% | -14.42% | 19.71% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.60 | -3.13 | -4.94 | -3.25 | -19.20 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 26.64 | 18.18 |
| Price-to-Book (P/B) Ratio | 0.52 | 0.66 | 0.55 | 0.44 | 1.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.81 | -3.73 | -6.35 | -6.93 | 5.07 |
| Price-to-Operating Cash Flow Ratio | -1.83 | -3.89 | -6.48 | -7.21 | 4.82 |
| Price-to-Earnings Growth (PEG) Ratio | -0.09 | -0.06 | 0.20 | -0.04 | -0.31 |
| Enterprise Value Multiple | 1.21 | 1.17 | 3.49 | 1.58 | -4.34 |
| Enterprise Value | -52.69M | -42.11M | -78.75M | -50.46M | 97.40M |
| EV to EBITDA | 1.21 | 1.17 | 3.49 | 1.58 | -4.34 |
| EV to Sales | 0.00 | 0.00 | 0.00 | -12.58 | 5.30 |
| EV to Free Cash Flow | 1.31 | 1.30 | 4.13 | 3.27 | 1.48 |
| EV to Operating Cash Flow | 1.32 | 1.36 | 4.21 | 3.40 | 1.40 |
| Tangible Book Value Per Share | 4.60 | 5.98 | 7.22 | 7.90 | 8.97 |
| Shareholders’ Equity Per Share | 4.60 | 5.98 | 7.22 | 7.90 | 8.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.00 | -0.01 | 0.02 | 0.32 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.13 | 0.61 |
| Net Income Per Share | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 |
| Tax Burden | 1.01 | 1.00 | 1.01 | 0.98 | 0.68 |
| Interest Burden | 1.00 | 1.02 | 1.00 | 0.97 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 7.87 | 1.54 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 1.57 | 0.51 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 1.26 | 0.24 |
| Income Quality | 0.88 | 0.80 | 0.76 | 0.45 | -3.99 |
Currency in USD
